Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RANI Rani Therapeutics Holdings

Pre-Mkt 05-18 08:32:06 EDT

1.08

-0.03

-2.70%

盘前1.07

-0.01-0.91%

08:27 EDT

High1.12	Low1.06	Vol994.05K
Open1.11	D1 Closing1.11	Amplitude5.40%
Mkt Cap133.59M	Tradable Cap72.24M	Total Shares123.69M
T/O1.08M	T/O Rate1.49%	Tradable Shares66.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RANI","market":"US","secType":"STK","nameCN":"Rani Therapeutics Holdings","latestPrice":1.08,"timestamp":1778875200000,"preClose":1.11,"halted":0,"volume":994049,"hourTrading":{"tag":"盘前","latestPrice":1.0702,"preClose":1.08,"latestTime":"08:27 EDT","volume":21806,"amount":23304.2880794,"timestamp":1779107253032,"change":-0.0098,"changeRate":-0.009074,"amplitude":0.037037},"delay":0,"changeRate":-0.02702702702702705,"floatShares":66891000,"shares":123692286,"eps":-0.45,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"05-18 08:32:06 EDT","open":1.11,"high":1.12,"low":1.0601,"amount":1081767.5617413,"amplitude":0.053964,"askPrice":1.17,"askSize":200,"bidPrice":0.9787,"bidSize":177,"shortable":3,"etf":0,"ttmEps":-0.45,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.0702,"preClose":1.08,"latestTime":"08:27 EDT","volume":21806,"amount":23304.2880794,"timestamp":1779107253032,"change":-0.0098,"changeRate":-0.009074,"amplitude":0.037037},"postHourTrading":{"tag":"盘后","latestPrice":1.0715,"preClose":1.08,"latestTime":"19:46 EDT","volume":22787,"amount":24708.0199,"timestamp":1778888776972,"change":-0.0085,"changeRate":-0.00787,"amplitude":0.046296},"volumeRatio":0.7856147967336716,"impliedVol":2.5172,"impliedVolPercentile":0.916},"requestUrl":"/m/hq/s/RANI/wiki","defaultTab":"wiki","newsList":[{"id":"2636254096","title":"Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2636254096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636254096?lang=en_us&edition=fundamental","pubTime":"2026-05-17 14:00","pubTimestamp":1778997655,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings, Inc. Class A (RANI) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rani Therapeutics Holdi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasdaq-delisting-risk-looms-as-rani-therapeutics-fails-to-meet-1-minimum-bid-price?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasdaq-delisting-risk-looms-as-rani-therapeutics-fails-to-meet-1-minimum-bid-price?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI","BK4007","NQmain","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635583650","title":"Rani Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635583650","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635583650?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:49","pubTimestamp":1778878190,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings SummaryRani Therapeutics Holdings Inc RANI.OQ reported a quarterly adjusted loss of 4 cents per share for the q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S24G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030742","title":"Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030742?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:34","pubTimestamp":1778877284,"startTime":"0","endTime":"0","summary":"The latest update is out from Rani Therapeutics Holdings ( ($RANI) ). Rani Therapeutics reported first-quarter 2026 results showing contract revenu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-faces-nasdaq-bid-price-noncompliance-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rani-therapeutics-faces-nasdaq-bid-price-noncompliance-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI","LENZ","BK4007","NQmain","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037402","title":"Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037402","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037402?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:14","pubTimestamp":1778876044,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transitionOverviewUS biotherapeutics firm's Q1 contract revenue rose, driven by Chugai collaborationQ1 net loss narro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037625","title":"Rani Therapeutics Holdings Inc - Svai Sanford to Remain CFO During Transition Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037625","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037625?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA45BKWQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037634","title":"Rani Therapeutics Q1 Operating Income USD -8.339 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037634?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX45C8EF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RANI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635903762","title":"Press Release: Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2635903762","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635903762?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":"- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill for the treatment of obesity in collaboration with ProGen --. - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer -. - Appointed Jesper Hiland as Head of Strategy and Dr. Sara Kenkare-Mitra as a Strategic Advisor --. SAN JOSE, Calif., May 15, 2026  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the first quarter ended March 31, 2026, provided a corporate update, and announced a Chief Financial Officer transition.\"Svai has been a key leader during a period of significant transformation for the Company,\" said Talat Imran, CEO. \"His leadership through the IPO and subsequent financing efforts strengthened our financial position and set the Company up well for its next phase of growth. We are grateful for his contributions and appreciate his commitment to supporting a smooth transition.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4595","09799","MSOO","WNTR","MSDD","MST","MSTK","MSTY","MTYY","MSTP","BK4232","BK4539","IMST","BK4585","SMST","MSTY.UK","MSTR","SMI3.UK","BK4516","MSTU","MSTZ","LMI3.UK","BK4007","07799","BK4139","3LMI.UK","3SMI.UK","BK4600","MSST","APED","R","BK4022","BK4588","BK4023","MSTW","BK4596","RANI","09399","MSTX","LENZ","07399","MSII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634565460","title":"Rani Therapeutics Holdings Inc  expected to post a loss of 4 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634565460","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634565460?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:46","pubTimestamp":1778276766,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc  expected to post a loss of4cents a share - Earnings Preview Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to  show a rise in quarterly revenue when it repor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628241374","title":"Rani Therapeutics Holdings announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628241374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628241374?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:47","pubTimestamp":1776372466,"startTime":"0","endTime":"0","summary":"Rani Therapeutics scheduled annual shareholder meeting for May 28, 2026 via live webcast.Shareholders will vote to elect seven director nominees to serve until next annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLjjXkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626864251","title":"Rani Therapeutics names Sara Kenkare-Mitra strategic advisor on platform, clinical strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626864251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626864251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:03","pubTimestamp":1775732635,"startTime":"0","endTime":"0","summary":"Rani Therapeutics appointed Sara Kenkare-Mitra as strategic advisor to shape platform and clinical strategy.Her remit includes therapeutic area focus, product selection, development prioritization, regulatory alignment, market positioning.Kenkare-Mitra most recently served as president and head of R&D at Alector.She previously spent more than 20 years at Genentech, working on development and approvals of multiple therapies and advancing antibody-drug conjugate platform.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL8dLyzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4539","IE00BKPKM429.USD","BK4588","BK4007","LU2210150020.SGD","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014039.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","RANI","ALEC","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624751179","title":"Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624751179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624751179?lang=en_us&edition=fundamental","pubTime":"2026-04-01 22:00","pubTimestamp":1775052020,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (AP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-rani-therapeutics-holdings-rani-and-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS","BK4539","XLV","BK4505","BK4137","LU0128526141.USD","BK4581","LU1093756168.USD","RANI","BK4139","XBI","BK4588","LU1093756325.SGD","BK4007","BK4585","LU0029874061.USD","LABU","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622922809","title":"Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622922809","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622922809?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:47","pubTimestamp":1774655267,"startTime":"0","endTime":"0","summary":"Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares. Rani Therapeutics Chief Technical Officer Alireza Javadi reported direct ownership of 10,075 shares of Class A common stock in an initial Form 3 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4D0JQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622894336","title":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622894336","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622894336?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:38","pubTimestamp":1774561121,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings SummaryRani Therapeutics Holdings Inc RANI.OQ reported a quarterly adjusted loss of 12 cents per share for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E2KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622349899","title":"Rani Therapeutics' net loss narrows in Q4 as costs fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2622349899","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622349899?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:26","pubTimestamp":1774556817,"startTime":"0","endTime":"0","summary":"Rani Therapeutics' net loss narrows in Q4 as costs fallOverviewU.S. biotherapeutics developer's Q4 net loss narrowed as operating expenses declinedCompany completed $60.3 mln private placement and ent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL1N40E154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896296","title":"Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896296?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:11","pubTimestamp":1774555868,"startTime":"0","endTime":"0","summary":"Rani published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.Contract revenue was USD 1.5 million in Q4 and USD 1.6 million in FY 2025, up 42.12% and 58.85%, respectively, driven mainly by revenue attributed to a license and collaboration agreement.Net loss was USD 9.1 million in Q4 and USD 41.0 million in FY 2025, narrowing 42.27% and 27.55%, respectively.R&D expense was USD 4.9 million in Q4 and USD 20.2 million in FY 2025, down 27.93% and 24.3%, respectively, primarily due to lower compensation costs and other cost-containment measures including pausing or terminating certain R&D programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3S7Tvm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RANI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622289660","title":"Rani Therapeutics Q4 Operating Expenses USD 9.995 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622289660?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nPLX5A12F0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RANI","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891613","title":"Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891613?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263414/0/en/Rani-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898713","title":"Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898713?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:20","pubTimestamp":1774549216,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is 1.1x normal with calls leading puts 24:1. Implied volatility suggests the marke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-holdings-options-imply-17-3-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-holdings-options-imply-17-3-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007889","title":"Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007889","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007889?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:53","pubTimestamp":1774471980,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., March 25, 2026  -- Rani Therapeutics Holdings, Inc.  , a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Hiland as Head of Strategy. Mr. Hiland has served as a strategic adviser to the company since 2023 and brings more than 30 years of global pharmaceutical leadership experience, including extensive expertise in obesity and metabolic disease.\"What attracted me to Rani is the strength of its platform and the breadth of opportunity it creates across multiple therapeutic areas,\" said Mr. Hiland. \"The ability to deliver biologics orally has the potential to reshape treatment paradigms, and I believe Rani i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","RANI","BK4007","BK4539","BK4022","LENZ","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013980","title":"Rani Therapeutics Holdings Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013980","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013980?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:26","pubTimestamp":1774383972,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc  expected to post a loss of7cents a share - Earnings Preview Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to  show a rise in quarterly revenue when it repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C2P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RANI","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ranitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1186},{"period":"1month","weight":0.125},{"period":"3month","weight":-0.129},{"period":"6month","weight":-0.4255},{"period":"1year","weight":0.8921},{"period":"ytd","weight":-0.2}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030292},{"month":2,"riseRate":0.8,"avgChangeRate":0.053306},{"month":3,"riseRate":0,"avgChangeRate":-0.236131},{"month":4,"riseRate":0.4,"avgChangeRate":0.191507},{"month":5,"riseRate":0.2,"avgChangeRate":-0.123515},{"month":6,"riseRate":0.25,"avgChangeRate":-0.118539},{"month":7,"riseRate":0.75,"avgChangeRate":-0.021139},{"month":8,"riseRate":0.4,"avgChangeRate":0.087585},{"month":9,"riseRate":0.2,"avgChangeRate":-0.146008},{"month":10,"riseRate":0.6,"avgChangeRate":0.658105},{"month":11,"riseRate":0.6,"avgChangeRate":0.053129},{"month":12,"riseRate":0.2,"avgChangeRate":-0.107417}],"exchange":"NASDAQ","name":"Rani Therapeutics Holdings","nameEN":"Rani Therapeutics Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rani Therapeutics Holdings,RANI,Rani Therapeutics Holdings股票,Rani Therapeutics Holdings股票老虎,Rani Therapeutics Holdings股票老虎国际,Rani Therapeutics Holdings行情,Rani Therapeutics Holdings股票行情,Rani Therapeutics Holdings股价,Rani Therapeutics Holdings股市,Rani Therapeutics Holdings股票价格,Rani Therapeutics Holdings股票交易,Rani Therapeutics Holdings股票购买,Rani Therapeutics Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rani Therapeutics Holdings(RANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rani Therapeutics Holdings(RANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}